Walk into any convenience store and you will find them: slim white pouches tucked in colorful cans, marketed under names like Zyn, On!, and Velo. Nicotine pouches have gone from invisible to ubiquitous in just a few years. Sales data tells the story starkly. Global sales grew from roughly 292 million units in 2018 to 20.1 billion units in 2023 [1]. That is a sixty-nine-fold expansion in five years. Approximately 85 percent of those purchases happened in the United States [1].
The numbers make one thing clear. Millions of people, many of them young adults who never smoked cigarettes, have picked up a new nicotine habit. The question that matters now is whether this shift represents genuine harm reduction or simply a different way to get addicted.
The Anatomy of a Nicotine Pouch
Unlike traditional smokeless tobacco products, nicotine pouches contain no tobacco leaf, dust, or stem [1]. They are filled with food-grade ingredients, flavorings, and nicotine extracted from tobacco plants. The main bulk ingredient is plant fiber, typically derived from eucalyptus and pine [1]. The pouches are designed to be placed between the upper lip and gum, where moisture allows nicotine to diffuse into the bloodstream over the course of up to an hour [2].
Zyn dominates the market. The brand holds more than 70 percent of global nicotine pouch sales [1]. Philip Morris International acquired Swedish Match, Zyn's parent company, in 2022 [2]. The company sold nearly 385 million Zyn cans globally in 2023, up 62 percent from 237 million the previous year [2]. A shortage occurred in May 2024 as demand outpaced production capacity [2].
Nicotine content varies by product and brand. Most pouches contain between 1 mg and 10 mg of nicotine per pouch, though some products deliver up to 50 mg [1]. That range matters. It means users can select products with widely different nicotine strength, often without fully understanding what they are consuming.
What the Research Actually Shows
Here is where the picture gets complicated. Several recent scientific reviews conclude that nicotine pouches expose users to substantially fewer tobacco-related toxicants than combustible cigarettes [1]. That is a meaningful statement. Cigarette smoke contains roughly 7,000 chemicals, including at least 70 known carcinogens. By that comparison, a pouch containing nicotine, flavorings, and plant fiber looks almost benign.
The International Agency for Research on Cancer classifies nicotine itself as non-carcinogenic [1]. The Royal College of Physicians has stated that nicotine in itself is not a hazardous drug [1]. These are significant positions from respected health bodies.
But nicotine is not harmless. The same Royal College of Physicians note that long-term nicotine use likely causes higher risks for cardiovascular diseases, stroke, and reproductive harms [1]. Nicotine constricts blood vessels. It raises heart rate and blood pressure. It is not a substance you would choose if safety were the priority.
Vaping presents a different risk profile. The health risks of vaping are generally considered less severe than smoking cigarettes, though not risk-free [3]. The nicotine absorption rate from vaping is slower than from cigarettes, which may reduce addiction potential [3]. Vaping has been shown to be more effective as a quitting tool than traditional nicotine replacement therapy [3].
The problem with pouches is that they are not marketed or used primarily as quitting aids. They are marketed as alternatives for people who already use nicotine or as products for situations where smoking or vaping is not allowed. Zyn's UK marketing slogan makes this explicit: "Can't smoke? Can't vape? Can Zyn." [2]
The Independent Research Problem
There is a fundamental issue with the evidence base that deserves attention. Many studies on nicotine pouch health effects are funded or conducted by the tobacco industry [1]. This is not a minor caveat. It is a structural problem that makes independent assessment difficult.
The WHO report on tobacco product regulation notes that there is limited independent testing of the constituents, exposure, or biomarkers of effects for nicotine pouches [4]. Long-term effects on oral, cardiovascular, and overall health remain uncertain [1]. The market has outpaced the science.
This matters for public health decisions. When a product grows from hundreds of millions of units to tens of billions in a few years, and the independent research lags behind, regulators and health professionals are operating with incomplete information.
The Youth Question
The rapid growth in sales has coincided with rising use among young people who never smoked cigarettes. This is the dimension that concerns public health authorities most.
Major health organizations, including the WHO, emphasize that nicotine pouches should not be used by youth, young adults, or pregnant individuals [1]. Nicotine exposure during adolescence can harm brain development, potentially affecting memory, attention, and impulse control.
The products are designed to be discrete. They require no battery, no device, no visible vapor. They can be used in classrooms, at desks, in places where smoking or vaping would be conspicuous. That discretion is a feature from a commercial standpoint. From a youth prevention standpoint, it is a problem.
The Price Gap
One factor driving the shift from cigarettes to pouches is cost. In the United States, oral nicotine pouches typically cost approximately 4.22 to 4.57 per can, compared to cigarettes at approximately 5.73 to 8.55 per pack [1]. Many states do not tax nicotine pouches at the same rate as other tobacco products [1]. That preferential treatment keeps prices lower and makes the transition financially attractive for existing smokers.
For someone trying to quit cigarettes, a lower-cost alternative with potentially reduced harm could represent a genuine benefit. For a young person experimenting with nicotine for the first time, the same price structure makes entry easier.
What We Do Not Know
The honest summary is this. Nicotine pouches almost certainly expose users to fewer harmful chemicals than cigarettes. That comparison is relevant for current smokers evaluating options. But for someone starting nicotine use who never smoked, the comparison to cigarettes is beside the point. The relevant question is what the health effects are on their own, and that question remains incompletely answered.
The regulatory landscape has not caught up. The FDA has not authorized nicotine pouches as quit-smoking aids [1]. In Norway, Finland, Canada, and other countries, these products are sold as nicotine replacement therapy through pharmacies [1]. In the United States, they are sold as consumer products with minimal restrictions.
The growth curve is not slowing. With Philip Morris International building a major production facility in Colorado to meet demand, the market for these products will continue expanding [2]. Independent researchers will continue playing catch-up.
The practical takeaway is straightforward. If you currently smoke cigarettes, switching to nicotine pouches likely reduces your exposure to harmful chemicals. If you do not currently use nicotine, starting with pouches carries unknown risks that the existing evidence cannot fully characterize. The science will catch up eventually. Until then, the uncertainty is worth noting.